Superluminal Medicines · Series A
AI biotech company developing small-molecule drugs that target G protein-coupled receptors
Amount
$120M
Round
Series A
Valuation
—
Announced
—
AI biotech company developing small-molecule drugs that target G protein-coupled receptors
Amount
$120M
Round
Series A
Valuation
—
Announced
—